H.C. Wainwright Announces Cryptocurrency & High-Performance Computing Programming at 27th Annual Global Investment Conference
PorAinvest
martes, 2 de septiembre de 2025, 8:35 am ET1 min de lectura
BTC--
PDS Biotechnology will be represented by Frank Bedu-Addo, Ph.D., Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, who will be available for one-on-one meetings with investors. The company's participation in the conference provides an opportunity for investors to engage with management and learn more about PDS Biotech's lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) is being developed in combination with standard-of-care immune checkpoint inhibitor pembrolizumab.
The conference is expected to attract a significant number of investors, including pension funds, endowments, and hedge funds, who are interested in exploring new investment opportunities in the cryptocurrency and high-performance computing sectors. The event will also provide a platform for companies to showcase their innovative technologies and discuss their growth prospects.
Investors interested in speaking with management should contact their H.C. Wainwright representative. For more information about PDS Biotechnology, please visit www.pdsbiotech.com [1].
References:
[1] https://www.morningstar.com/news/globe-newswire/9519933/pds-biotech-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference
[2] https://www.ainvest.com/news/strategic-consolidation-bitcoin-mining-sector-gryphon-american-bitcoin-merger-institutional-implications-2508/
PDSB--
H.C. Wainwright is hosting its 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel. The conference will feature presentations from leading public companies in cryptocurrency and high-performance computing, as well as keynote speakers, including Michael Saylor and George W. Bush. Panels will also be held on treasury strategy and Bitcoin mining & high-performance computing.
PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company, has announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference, set to take place from September 8-10, 2025, at the Lotte New York Palace Hotel. The conference will feature presentations from leading public companies in cryptocurrency and high-performance computing, as well as keynote speakers, including Michael Saylor and George W. Bush. Panels will also be held on treasury strategy and Bitcoin mining & high-performance computing.PDS Biotechnology will be represented by Frank Bedu-Addo, Ph.D., Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, who will be available for one-on-one meetings with investors. The company's participation in the conference provides an opportunity for investors to engage with management and learn more about PDS Biotech's lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead investigational targeted immunotherapy PDS0101 (Versamune® HPV) is being developed in combination with standard-of-care immune checkpoint inhibitor pembrolizumab.
The conference is expected to attract a significant number of investors, including pension funds, endowments, and hedge funds, who are interested in exploring new investment opportunities in the cryptocurrency and high-performance computing sectors. The event will also provide a platform for companies to showcase their innovative technologies and discuss their growth prospects.
Investors interested in speaking with management should contact their H.C. Wainwright representative. For more information about PDS Biotechnology, please visit www.pdsbiotech.com [1].
References:
[1] https://www.morningstar.com/news/globe-newswire/9519933/pds-biotech-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference
[2] https://www.ainvest.com/news/strategic-consolidation-bitcoin-mining-sector-gryphon-american-bitcoin-merger-institutional-implications-2508/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios